Therapeutics case studies

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

The client tasked ICON plc with managing six phase 3 clinical trials, with overlapping timelines, to further evaluate this
drug in patients with AD.

The client was conducting a a pharmaco-epidemiologic study to characterise the impacts and burden of Achondroplasia across the lifespan.

ICON successfully overcame site activation and patient recruitment challenges in an early Parkinson’s disease (PD) study.

A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.

A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.

Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.

ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.

Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.

Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.

Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.

A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.